Research Analysts Issue Forecasts for ELAN FY2025 Earnings

Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) - Equities research analysts at William Blair raised their FY2025 EPS estimates for shares of Elanco Animal Health in a research note issued to investors on Wednesday, May 7th. William Blair analyst B. Vazquez now expects that the company will post earnings of $0.83 per share for the year, up from their previous estimate of $0.80. The consensus estimate for Elanco Animal Health's current full-year earnings is $0.91 per share. William Blair also issued estimates for Elanco Animal Health's Q1 2026 earnings at $0.31 EPS.

Several other brokerages have also issued reports on ELAN. Piper Sandler lowered their price target on shares of Elanco Animal Health from $16.00 to $12.00 and set a "neutral" rating on the stock in a report on Thursday, March 6th. Morgan Stanley lowered their target price on shares of Elanco Animal Health from $14.00 to $13.00 and set an "equal weight" rating on the stock in a research note on Wednesday, February 26th. UBS Group cut their price target on shares of Elanco Animal Health from $18.00 to $17.00 and set a "buy" rating for the company in a research note on Wednesday, February 26th. Barclays decreased their price objective on Elanco Animal Health from $20.00 to $19.00 and set an "overweight" rating on the stock in a report on Wednesday, February 26th. Finally, Stifel Nicolaus increased their target price on Elanco Animal Health from $13.00 to $15.00 and gave the stock a "buy" rating in a report on Thursday, May 8th. Four research analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to MarketBeat, the company presently has an average rating of "Hold" and a consensus price target of $15.00.

Elanco Animal Health Stock Performance

Shares of NYSE ELAN traded down $0.14 during trading hours on Monday, reaching $12.88. The stock had a trading volume of 6,545,420 shares, compared to its average volume of 5,025,733. The company has a market cap of $6.40 billion, a price-to-earnings ratio of 32.20, a PEG ratio of 2.50 and a beta of 1.49. Elanco Animal Health has a twelve month low of $8.02 and a twelve month high of $18.80. The business's fifty day moving average is $9.97 and its two-hundred day moving average is $11.43. The company has a debt-to-equity ratio of 0.66, a current ratio of 2.55 and a quick ratio of 1.31.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last issued its quarterly earnings results on Wednesday, May 7th. The company reported $0.37 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.31 by $0.06. The firm had revenue of $1.19 billion for the quarter, compared to analyst estimates of $1.17 billion. Elanco Animal Health had a return on equity of 6.78% and a net margin of 4.60%. The company's quarterly revenue was down 1.0% compared to the same quarter last year. During the same period in the previous year, the company posted $0.34 earnings per share.

Institutional Investors Weigh In On Elanco Animal Health

A number of hedge funds have recently added to or reduced their stakes in ELAN. Allworth Financial LP lifted its position in shares of Elanco Animal Health by 791.7% during the first quarter. Allworth Financial LP now owns 2,354 shares of the company's stock worth $25,000 after purchasing an additional 2,090 shares in the last quarter. Wilmington Savings Fund Society FSB bought a new position in Elanco Animal Health in the 3rd quarter worth approximately $35,000. CoreCap Advisors LLC acquired a new position in Elanco Animal Health during the 4th quarter worth $29,000. Parallel Advisors LLC boosted its position in Elanco Animal Health by 92.2% in the 1st quarter. Parallel Advisors LLC now owns 3,860 shares of the company's stock valued at $41,000 after buying an additional 1,852 shares during the last quarter. Finally, NBC Securities Inc. acquired a new stake in shares of Elanco Animal Health in the 1st quarter valued at $40,000. Institutional investors own 97.48% of the company's stock.

Insider Transactions at Elanco Animal Health

In other Elanco Animal Health news, Director Lawrence Erik Kurzius purchased 10,000 shares of the business's stock in a transaction that occurred on Tuesday, March 11th. The stock was acquired at an average cost of $10.20 per share, with a total value of $102,000.00. Following the completion of the acquisition, the director now directly owns 111,459 shares of the company's stock, valued at $1,136,881.80. This represents a 9.86% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 0.89% of the company's stock.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.